Table of Contents
- Trial overview
- Who is being studied
- Trial phases and study designs
- What the trials measure
- Key trials of Zamtocabtagene Autoleucel
- Long-term follow-up study
- Patient glossary in context
Trial overview
The available studies of Zamtocabtagene Autoleucel are focused on blood cancers, especially relapsed or refractory diffuse large B cell lymphoma and other mature B cell neoplasms.[1][2][3]
Across the trial records, the study product is listed as MB-CART2019.1, and the trials are authorised and interventional, meaning people receive a study treatment rather than only being observed.[1][2][3]
Who is being studied
One group includes people with relapsed/refractory diffuse large B cell lymphoma, meaning the lymphoma came back or did not respond to earlier treatment.[1][2]
Another study includes children and adolescents with relapsed or refractory mature B cell neoplasms, including people with primary refractory disease, which means the cancer did not respond to the first treatment.[3]
The long-term follow-up study includes several groups with B cell malignancies and also lists other cancer groups in its condition description, showing that it is designed to follow patients after earlier cell therapy studies.[4]
Trial phases and study designs
Most of the Zamtocabtagene Autoleucel studies are in Phase 2, which usually means the researchers are looking more closely at how well the treatment works while still watching safety.[1][2][3]
One study is a Phase 1 long-term follow-up trial, which is mainly about safety over time rather than first testing whether the treatment works.[4]
The Phase 2 studies use different treatment plans. One compares MB-CART2019.1 with standard of care therapy called R-GemOx, while another tests MB-CART2019.1 after a conditioning lymphodepletion regimen, which is treatment given before the study infusion to prepare the body.[1][2]
What the trials measure
In the DALY 2-EU study, the main outcome is event-free survival (EFS), which measures how long people stay free from cancer progression, treatment failure, or death.[1]
In the USA Phase 2 study, the main outcome is objective response rate (ORR), which is the percentage of people whose cancer shrinks or disappears based on the study review rules.[2]
In the pediatric and adolescent study, the main outcomes include safety measures such as adverse events, serious adverse events, and adverse events of special interest, along with best objective response rate (BORR), which counts the best response seen after infusion.[3]
The long-term follow-up study looks for late-onset adverse reactions, serious adverse events, serious adverse reactions, relapse or progression of the disease, life-threatening infections, death from any cause, and new or secondary cancers.[4]
Key trials of Zamtocabtagene Autoleucel
NCT04844866, DALY 2-EU, is a Phase 2 study with 232 planned participants who have relapsed or refractory diffuse large B cell lymphoma and are not eligible for high-dose chemotherapy and autologous stem cell transplantation (ASCT), which is a stem cell transplant using the patient’s own cells.[1]
This study has two parts: Part I compares MB-CART2019.1 with standard care using R-GemOx, and Part II evaluates MB-CART2019.1 in younger, fit participants with the same disease.[1]
NCT04792489 is another Phase 2 study in relapsed or refractory diffuse large B cell lymphoma with 110 planned participants, and it looks at the best overall response after MB-CART2019.1 is given following conditioning lymphodepletion.[2]
NCT06508951 is a Phase 2 study in 12 children and adolescents with relapsed or refractory mature B cell neoplasms, and it focuses on both safety and best overall response after treatment.[3]
Long-term follow-up study
2022-501648-14-00 is a Phase 1 long-term follow-up study with 40 planned participants, designed to evaluate safety after treatment with Miltenyi CAR T cell therapy.[4]
The trial tracks late adverse reactions and serious events over time, which helps researchers understand how patients do after treatment beyond the first study period.[4]
Patient glossary in context
Relapsed means the cancer came back after treatment, while refractory means it did not respond well to treatment.[1][2][3]
Interventional means the study gives a treatment and measures the results, rather than only watching what happens.[1][2][3][4]
Autologous stem cell transplantation means a transplant using the patient’s own stem cells, and some trial participants are not eligible for this treatment.[1]
Adverse events are unwanted medical problems that happen during a study, and serious adverse events are the more severe ones.[3][4]
